ARTRYA®
Coronary Artery Disease.
We see you.

# Artrya expands U.S. commercial momentum with five-year HonorHealth agreement

## Five-year agreement with major Arizona health system demonstrates growing U.S. demand and broadens Salix® customer acquisition

**PERTH, Australia, 13 November 2026**: Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease globally, is pleased to announce a five-year commercial agreement with major Arizona health system HonorHealth, with a minimum contracted value of US$0.5 million.

HonorHealth becomes Artrya's fifth U.S. commercial customer and, importantly, its first inbound customer secured outside the Company's foundation customers and SAPPHIRE study participants. The agreement represents another important milestone in Artrya's U.S. commercial roll-out, demonstrating growing market awareness of Salix® and broadening customer acquisition channels.

## Key Points

- **HonorHealth becomes Artrya's fifth U.S. commercial customer and first secured outside its foundation customers and SAPPHIRE research programs – demonstrating growing market awareness of Salix® and expanding customer acquisition channels.**
- **Five-year commercial agreement with recurring and usage-based revenue potential – minimum contracted value of US$0.5M for Salix® Coronary Anatomy, with additional fee-per-scan revenue from Salix® Coronary Plaque and Salix® Coronary Flow following FDA clearance.**
- **Major Arizona health system serving approximately five million people – nine acute-care hospitals providing CCTA, supported by HonorHealth Heart Care's network of 40 cardiac specialist offices.**
- **Salix® to be deployed across HonorHealth's CCTA network – providing an opportunity to demonstrate the platform's scalability and commercial potential across a major U.S. health system.**
- **Builds on the recent Huntsville commercial agreement – supporting HonorHealth's vision to expand CCTA capacity, improve clinical workflows and explore the development of a leading cardiovascular imaging Centre of Excellence in Arizona.**
- **HonorHealth's academic affiliation creates opportunities for future clinical research and innovation – as primary clinical affiliate of Arizona State University (ASU) John Shufeldt School of Medicine and Medical Engineering, providing a potential pathway for collaborative AI research and development.**

**John Konstantopoulos, Co-Founder and CEO of Artrya, commented:**

*"The HonorHealth agreement is another major step forward in our U.S. commercial roll-out and, importantly, represents our first inbound U.S. customer. Coming shortly after Huntsville Health became our first SAPPHIRE study partner to convert to a commercial customer, it demonstrates growing awareness of Salix® and commercial momentum across multiple channels of our U.S. strategy.*

*HonorHealth is an exciting customer for Artrya. It is a major U.S. health system with a strong focus on using advanced medical imaging technology to improve clinical workflows and patient care. Through its evaluation of Salix®, we have already developed a strong relationship with HonorHealth's clinical and leadership teams and demonstrated the value our platform can bring to its CCTA program.*

*The scale of HonorHealth is also significant. With nine acute-care hospitals across Phoenix and Scottsdale providing CCTA, the network provides a meaningful opportunity to demonstrate the scalability and commercial potential of Salix® across a large health system.*

*Importantly, our shared vision extends beyond the initial deployment of Salix®. We see an opportunity to help HonorHealth increase CCTA capacity, embed advanced coronary assessment into routine clinical care and, over time, explore the development of a leading cardiovascular imaging Centre of Excellence in Arizona that could serve as a reference for other U.S. health systems.*

*Our immediate focus is now on successful implementation and driving clinical adoption across the HonorHealth network."*

**Dr. Joshua Kim, D.O., Network Director of Advanced Medical Imaging at HonorHealth, commented:**

*"Cardiovascular disease remains one of the most significant health challenges facing the communities we serve. As heart care continues to evolve quickly, HonorHealth Heart Care is committed to stay ahead of that, not just by adopting new technologies, but by building the teams and systems needed to deliver them effectively. We are also heavily focused on prevention over treatment for our patients. These are the reasons we have selected Salix® over other technologies we considered, to seamlessly and more effectively manage our growing clinical workflows of patients with coronary artery disease. We also see strong benefits from the way Salix® can support earlier and more precise decisions to better manage our patients.*

## Expanding U.S. commercial adoption

The agreement with HonorHealth further expands Artrya's U.S. commercial customer base and represents another important step in the Company's plans to establish Salix® within leading healthcare organisations.

As a top 100 U.S. health system, the Artrya engagement team included all key disciplines of technical, clinical and I.T., and has worked through a detailed Salix® demonstration and validation stage within the HonorHealth Heart Care, led by the Network Director of Advanced Medical Imaging, Dr. Kim.

The system wide integration and deployment of Salix® will be across the hospitals within HonorHealth's network which all provide CCTA scans. This extends Artrya's U.S. commercial footprint and provides another large reference customer to help broader market adoption. As Artrya's second largest customer, this agreement will also expand the revenue potential for Artrya, although no estimates of CCTA scan numbers are provided.

Under the agreement, Salix® Coronary Anatomy will generate recurring SaaS subscription revenue, with additional fee-per-scan revenue from CCTA assessments performed with Salix® Coronary Plaque and, following FDA clearance, Salix® Coronary Flow. The US$0.5M minimum contracted value relates to Salix® Coronary Anatomy and does not include potential additional usage-based revenue from assessments with the Plaque and Flow modules.

The Agreement has a 5-year term with standard provisions for events of default and customary terms include security and privacy protocols, support levels and software upgrades.

## Building a cardiovascular imaging Centre of Excellence in Arizona

HonorHealth has outlined an ambition to develop a leading coronary CT angiography (CCTA) program in Arizona. The proposed pathway envisages an initial focus on embedding Salix® into clinical workflows, followed by growth in physician adoption, CCTA capacity and use of the platform's coronary assessment modules.

Over the longer term, HonorHealth and Artrya intend to explore the development of a recognised cardiovascular imaging Centre of Excellence, potentially supporting real-world clinical evidence, education, training and a reference model for broader U.S. adoption.

## About HonorHealth

HonorHealth is one of Arizona's largest non-profit healthcare systems, serving a population of approximately five million people across the greater Phoenix and Scottsdale metropolitan areas. The HonorHealth system operates nine acute-care hospitals each of which provide specialist services including coronary CT angiography or CCTA scans. As

part of their strong focus and expertise in managing and treating heart health, the HonorHealth Heart Care provides a central hub for 40 cardiac specific offices, offering a range of patient care from diagnosis to treatment.

The HonorHealth system also includes 200 primary, specialist and urgent care locations across Arizona, supported by more than 17,000 team members and 4,000 medical staff. HonorHealth also operates the HonorHealth Research Institute and is the primary clinical affiliate of the ASU John Shufeldt School of Medicine and Medical Engineering.

**- Ends -**

This ASX Announcement is authorised for release by the Board of Artrya Limited.

### About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to Identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through Innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit **www.artrya.com** or follow us on LinkedIn at **www.linkedin.com/company/artrya**

## For more information:

**Corporate Enquiries**

**John Konstantopoulos**
Co-Founder and Chief Executive Officer
Tel: +61 8 6478 7816
Email: contact@artrya.com

**Investor & Media Enquiries**

**David Allen or John Granger**
Hawkesbury Partners
Tel: +61 499 100 038 or +61 410 577 155
Email: investors@artrya.com

## Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.